Expression of IGLL1 Gene and Its Clinical Significance in Pediatric T-ALL.
10.19746/j.cnki.issn.1009-2137.2023.04.011
- Author:
Shui-Yan WU
1
;
Xin-Ran CHU
2
;
Qi JI
2
;
Xiao-Chen LIN
3
;
Zhen-Jiang BAI
3
;
Jian-Qin LI
2
;
Jian PAN
2
;
Zi-Xing CHEN
4
;
Shao-Yan HU
5
Author Information
1. Intensive Care Unit, Department of Pediatric Hematology &Oncology, Children's Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.
2. Department of Pediatric Hematology &Oncology, Children's Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.
3. Intensive Care Unit, Children's Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.
4. Department of Hematology, The First Affiliated People's Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.
5. Department of Pediatric Hematology &Oncology, Children's Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China. E-mail: hsy139@126.com.
- Publication Type:Journal Article
- Keywords:
T-cell acute lymphoblastic leukemia;
overall survival;
relapse-free survival
- MeSH:
Child;
Humans;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Clinical Relevance;
Disease-Free Survival;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics*;
Prednisone/therapeutic use*;
Prognosis;
Recurrence;
Immunoglobulin Light Chains, Surrogate/genetics*
- From:
Journal of Experimental Hematology
2023;31(4):999-1004
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To detect the relative expression of IGLL1 (immunoglobulin lambda-like polypeptide 1) mRNA in bone marrow of children with T-cell acute lymphoblastic leukemia (T-ALL), and analyze its correlation with the clinical characteristics and prognosis of the patients, so as to clarify the clinical significance of IGLL1 in pediatric T-ALL patients.
METHODS:A total of 56 pediatric T-ALL patients hospitalized in Children's Hospital of Soochow University from June 2012 to December 2017 and treated with CCLG-ALL 2008 regimen were selected. Transcriptome sequencing technology was used to detect the transcription level of IGLL1 gene in children with T-ALL. According to 25% of the IGLL1 transcription level (cutoff value:448), the enrolled children were divided into IGLL1 low expression group (17 cases) and IGLL1 high expression group (39 cases). Combined with clinical data, the correlation between the expression level of IGLL1 and prognosis of the patients was analyzed.
RESULTS:The comparative analysis showed that the transcription level of IGLL1 was not correlated with the clinical characteristics of the patients, such as sex, age, bone marrow blast, white blood cell (WBC) count at initial diagnosis. The 5-year OS rate of patients with high IGLL1 expression was significantly higher than that of patients with low IGLL1 expression (76.9%±6.7% vs 47.1%±12.1%, P =0.018). Further comparison of relapse-free survival (RFS) rate between the two groups showed that the 5-year RFS rate of patients with high IGLL1 expression was higher than that of patients with low IGLL1 expression, but the difference between the two groups was not statistically significant (P =0.095). Multivariate COX analysis was conducted on common clinical prognostic factors (age, sex, WBC count at diagnosis, prednisone response on the 7th day, bone marrow response on the 15th day after treatment) and IGLL1 expression level, and the results showed that IGLL1 expression (P =0.012) and prednisone response (P =0.017) were independent risk factors for overall survival in pediatric T-ALL patients.
CONCLUSION:In pediatric T-ALL, the OS rate of children with high expression of IGLL1 gene was significantly higher than that of children with low expression of IGLL1 gene, and the expression level of IGLL1 gene was an independent factor affecting the survival of children with T-ALL, which suggests that IGLL1 is a marker of good clinical prognosis of children with T-ALL.
